BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18256112)

  • 1. Forgiveness of non-adherence to HIV-1 antiretroviral therapy.
    Shuter J
    J Antimicrob Chemother; 2008 Apr; 61(4):769-73. PubMed ID: 18256112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting and monitoring antiretroviral adherence.
    Gross R
    LDI Issue Brief; 2007; 13(2):1-4. PubMed ID: 18354853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adherence to antiretroviral therapy during HIV infection, a multidisciplinary approach].
    Slama L; Le Camus C; Amiel C; Pialoux G; Gharakhanian S
    Med Mal Infect; 2006 Jan; 36(1):16-26. PubMed ID: 16325363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Solving the puzzle" of current HAART: what key strategic trials are needed?
    Carosi G; Torti C
    New Microbiol; 2004 Apr; 27(2 Suppl 1):127-30. PubMed ID: 15646075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for improving patient adherence to therapy and long-term patient outcomes.
    Battaglioli-DeNero AM
    J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S17-22. PubMed ID: 17275718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.
    Taiwo B; Hicks C; Eron J
    J Antimicrob Chemother; 2010 Jun; 65(6):1100-7. PubMed ID: 20348088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal drug treatment regimens for HIV depend on adherence.
    Krakovska O; Wahl LM
    J Theor Biol; 2007 Jun; 246(3):499-509. PubMed ID: 17320115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
    Lagnese M; Daar ES
    Expert Opin Pharmacother; 2008 Apr; 9(5):687-700. PubMed ID: 18345948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
    Wilson LE; Gallant JE
    Clin Infect Dis; 2009 Jan; 48(2):214-21. PubMed ID: 19072245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008.
    Sungkanuparph S; Anekthananon T; Hiransuthikul N; Bowonwatanuwong C; Supparatpinyo K; Mootsikapun P; Chetchotisakd P; Kiertiburanakul S; Tansuphaswadikul S; Buppanharun W; Manosuthi W; Techasathit W; Ratanasuwan W; Tantisiriwat W; Suwanagool S; Leechawengwongs M; Ruxrungtham K;
    J Med Assoc Thai; 2008 Dec; 91(12):1925-35. PubMed ID: 19133532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [AIDS treatment in Africa: the risk of antiretroviral resistance].
    Hamers RL; Schuurman R; van Vugt M; Derdelinckx I; Rinke de Wit TF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(48):2666-71. PubMed ID: 18179083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.
    Protopopescu C; Raffi F; Roux P; Reynes J; Dellamonica P; Spire B; Leport C; Carrieri MP;
    J Antimicrob Chemother; 2009 Sep; 64(3):599-606. PubMed ID: 19602563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients.
    Glass TR; De Geest S; Hirschel B; Battegay M; Furrer H; Covassini M; Vernazza PL; Bernasconi E; Rickenboch M; Weber R; Bucher HC;
    Antivir Ther; 2008; 13(1):77-85. PubMed ID: 18389901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvements in antiretroviral therapy outcomes over calendar time.
    Boyd MA
    Curr Opin HIV AIDS; 2009 May; 4(3):194-9. PubMed ID: 19532050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to antiretroviral therapy: how much is enough?
    Gulick RM
    Clin Infect Dis; 2006 Oct; 43(7):942-4. PubMed ID: 16941381
    [No Abstract]   [Full Text] [Related]  

  • 19. Levels of adherence required for virologic suppression among newer antiretroviral medications.
    Kobin AB; Sheth NU
    Ann Pharmacother; 2011 Mar; 45(3):372-9. PubMed ID: 21386024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When to start antiretroviral therapy: a swinging pendulum?
    Gallant JE
    Top HIV Med; 2008; 16(2):82-8. PubMed ID: 18591715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.